PXD013859

PXD013859 is an original dataset announced via ProteomeXchange.

Title	XPO1 is a critical player for Bortezomib resistance in Multiple Myeloma: A quantitative proteomic approach
Description	Among the blood cancers, 13% mortality is caused by Multiple myeloma (MM) type of haematological malignancy. In spite of therapeutic advances in chemotherapy treatment, still MM remains an incurable disease is mainly due to emergence of chemoresistance. At present time, FDA approved bortezomib is the first line drug for MM treatment. However, like other chemotherapy, MM patients are acquiring resistance against bortezomib. The present study aims to identify and validate bortezomib resistant protein targets in MM using iTRAQ and label free quantitative proteomic approaches. 125 differentially expressed proteins were commonly found in both approaches with similar differential expression pattern. XPO1 protein was selected for further validation as its significant high expression was observed in both iTRAQ and label free analysis. Bioinformatic analysis of these common differentially expressed proteins showed a clear cluster of proteins such as SMC1A, RCC2, CSE1, NUP88, NUP50, TPR, HSPA14, DYNLL1, RAD21 and RANBP2 being associated with XPO1. Functional studies like cell count assay, flow cytometry assay and soft agar assay proved that XPO1 knock down in RPMI 8226R cell line results in re-sensitization to bortezomib drug
HostingRepository	PRIDE
AnnounceDate	2024-10-22
AnnouncementXML	Submission_2024-10-22_04:56:54.660.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Srikanth Rapole
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	iTRAQ4plex-116 reporter+balance reagent acylated residue; monohydroxylated residue; iodoacetamide derivatized residue
Instrument	Orbitrap Fusion

Revision	Datetime	Status	ChangeLog Entry
0	2019-05-15 05:51:34	ID requested
1	2019-09-09 04:22:34	announced
⏵ 2	2024-10-22 04:56:55	announced	2024-10-22: Updated project metadata.

10.1016/j.jprot.2019.103504;

Chanukuppa V, Paul D, Taunk K, Chatterjee T, Sharma S, Kumar S, Santra MK, Rapole S, XPO1 is a critical player for bortezomib resistance in multiple myeloma: A quantitative proteomic approach. J Proteomics, 209():103504(2019) [pubmed]

submitter keyword: Label free analysis, Chemoresistance, Bortezomib, XPO1,Multiple myeloma, iTRAQ

Srikanth Rapole
contact affiliation	Proteomics Lab, National Centre for Cell Science (NCCS), Pune-411007, Maharashtra, India.
contact email	rsrikanth@nccs.res.in
lab head
Srikanth Rapole
contact affiliation	NCCS, Pune
contact email	nccsproteomics@gmail.com
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/09/PXD013859

PRIDE project URI

• PRIDE
  1. PXD013859
     1. Label: PRIDE project
     2. Name: XPO1 is a critical player for Bortezomib resistance in Multiple Myeloma: A quantitative proteomic approach